<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Daily Grok News</title>
    <style> body { font-family: Arial; max-width: 800px; margin: 0 auto; padding: 20px; } </style>
</head>
<body>
    <h1>Today's Top News (via Grok)</h1>
    <div id="news-content"><ul><li><a href="story1.html">Global Leaders Convene for Urgent Climate Summit in Paris</a>: World leaders gathered in Paris today for an emergency climate summit amid escalating extreme weather events worldwide. Discussions focus on binding emission reduction targets and funding for vulnerable nations. Experts warn that without immediate action, irreversible damage could occur within the decade.</li><li><a href="story2.html">Breakthrough in AI Ethics: New Global Framework Adopted by Tech Giants</a>: Leading tech companies unveiled a unified AI ethics framework today, aiming to curb misuse of artificial intelligence worldwide. The initiative includes mandatory transparency in algorithms and bias audits. Critics praise it as a step forward, but question its enforceability amid rapid tech advancements.</li><li><a href="story3.html">US-China Trade Talks Resume Amid Economic Tensions</a>: High-level US-China trade negotiations restarted today in Geneva, seeking to ease ongoing tariffs and supply chain disruptions. Both sides expressed optimism for a breakthrough on semiconductor exports. Analysts predict a deal could stabilize global markets but warn of underlying geopolitical frictions.</li><li><a href="story4.html">SpaceX Achieves First Crewed Mars Orbit Mission</a>: SpaceX successfully launched and orbited a crewed mission around Mars today, a historic milestone in human space exploration. The four-person team will conduct scientific experiments for six months. This paves the way for future landings and potential colonization efforts.</li><li><a href="story5.html">Breakthrough Vaccine Trial Shows Promise Against New COVID Variant</a>: A new mRNA vaccine targeting the emerging Omicron sub-variant XE demonstrated 92% efficacy in early trials, announced today by Pfizer-BioNTech. Health officials urge booster campaigns to prevent a winter surge. This development offers hope for sustained pandemic control amid rising cases in Europe and Asia.</li></ul></div>
    <p>Last updated: 10/17/2025, 3:02:40 PM</p>
</body>
</html>
